PharmaCyte Biotech, Inc.
PMCB Nasdaq
SEC CIK 1157075
Follow PharmaCyte Biotech
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$5.1M
+39.2% vs same quarter last year
EPS, diluted
−$0.54
+56.1% vs same quarter last year
Operating cash flow
−$780.9K
+60.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $0 | −$19.4M |
| FY25 | $0 | $30.7M |
| FY24 | $0 | $333.8K |
| FY23 | $0 | −$4.3M |
| FY22 | $0 | −$4.2M |
| FY21 | $0 | −$3.6M |
| FY20 | $0 | −$3.8M |
| FY19 | $0 | −$4.1M |
| FY18 | $0 | −$6.8M |
| FY17 | $0 | −$4.4M |
| FY16 | $0 | −$6.1M |
| FY15 | $0 | −$9.9M |
| FY14 | $0 | −$27.3M |
| FY13 | $12.2K | −$1.6M |
| FY12 | $66.6K | −$1.9M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY26 | $401.6K |
| FY25 | $2.5M |
| FY24 | $28.2M |
| FY23 | $13.6M |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |